Peng L, et al. – The researchers motive behind this study was to assess the clinical outcome of continuous epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment in combination with chemotherapy (combination group) versus continuous EGFR TKI treatment only (monotherapy group) in such a clinical setting. The study findings suggested that compared with EGFR TKI monotherapy, its combination with chemotherapy beyond gradual progression might not confer a significant survival benefit to non-small cell lung cancer (NSCLC) patients.